Sector News

J&J completes acquisition of Alios Biopharma

November 12, 2014
Life sciences
Johnson & Johnson (J&J) announced the completion of the acquisition of Alios BioPharma, Inc., a privately held clinical stage biopharmaceutical company focused on developing therapies for viral diseases, for a total purchase price of approximately $1.75 billion in cash.
 
With this acquisition complete, Alios BioPharma will now become part of the infectious diseases therapeutic area of the Janssen Pharmaceutical Companies of Johnson & Johnson.  The acquisition includes Alios BioPharma’s portfolio of potential therapeutics for viral infections with the promising compound AL-8176, an orally administered antiviral therapy currently in phase 2 studies for the treatment of infants with respiratory syncytial virus (RSV).  RSV is the last of the major paediatric diseases that currently has no effective therapy.  The acquisition also includes two early-stage compounds for hepatitis C (HCV) that could potentially augment Janssen’s existing HCV portfolio.
 
“The acquisition of Alios BioPharma further reflects our commitment to bringing together the best science from around the globe to address significant unmet need.   Together we will further strengthen Janssen’s infectious diseases pipeline to address the needs of patients and families affected by some of the world’s most devastating diseases,” said Paul Stoffels, M.D., chief scientific officer of Johnson & Johnson and Worldwide chairman, pharmaceuticals.
 
Source: pharmabiz

comments closed

Related News

July 21, 2024

CordenPharma invests €900m in peptide platform expansion

Life sciences

CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.

July 21, 2024

DSM-Firmenich to sell MEG-3 fish oil business to KD Pharma Group

Life sciences

DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.

July 21, 2024

Veranova appoints Cécile Maupas as Senior Vice President, Chief Commercial Officer

Life sciences

Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.

How can we help you?

We're easy to reach